ReviewCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2018
A Review of Prostate Cancer Genome-Wide Association Studies (GWAS).
Review in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Pooled it
- Genetically adjusted PSA levels for prostate cancer screening.Nature medicine · 2023Pooled it
- The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches.Prostate cancer and prostatic diseases · 2022Pooled it
- Article
- Exploring Genetic Contributions to Prostate Cancer Risk in an Asian Population-Based Study.Cancer medicine · 2026Article
- Exploring the genetic overlap between obstructive sleep apnea and prostate cancer.Journal of the National Cancer Center · 2026Article
- Development and Validation of a Genome-Wide Association Study Based Polygenic Risk Score for Prostate Cancer in an Asian Population.The world journal of men's health · 2026Article
- BaGPipe: an automated, reproducible, and flexible pipeline for bacterial genome-wide association studies.BMC microbiology · 2026Article
- Polygenic risk and germline genetics for prostate cancer in Asians: Where do we stand?Investigative and clinical urology · 2026Review
- Integrative genomic profiling identifies MLPH as a candidate gene in prostate cancer.Frontiers in medicine · 2026Article
- Association of selectedPathology oncology research : POR · 2026Article
- IP-SNPs-seq links noncoding risk alleles to lineage transcription factor programs in prostate cancer.Cellular and molecular life sciences : CMLS · 2025Article
- Review
- Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus.Nature communications · 2025Article
- Polygenic risk score (PRS) as prostate cancer screening: ready for primetime?Annals of translational medicine · 2025Article
- Review
- From conventional therapy to novel nano-based approaches. A focus on prostate cancer.Nanomedicine (London, England) · 2025Review
- VADEr: Vision Transformer-Inspired Framework for Polygenic Risk Reveals Underlying Genetic Heterogeneity in Prostate Cancer.medRxiv : the preprint server for health sciences · 2025Article
- Identifying Rare Germline Variants Associated with Metastatic Prostate Cancer Through an Extreme Phenotype Study.medRxiv : the preprint server for health sciences · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prostate cancer is the most common cancer in men in Europe and the United States. The genetic heritability of prostate cancer is contributed to by both rarely occurring genetic variants with higher penetrance and moderate to commonly occurring variants conferring lower risks. The number of identified variants belonging to the latter category has increased dramatically in the last 10 years with the development of the genome-wide association study (GWAS) and the collaboration of international consortia that have led to the sharing of large-scale genotyping data. Over 40 prostate cancer GWAS have been reported, with approximately 170 common variants now identified. Clinical utility of these variants could include strategies for population-based risk stratification to target prostate cancer screening to men with an increased genetic risk of disease development, while for those who develop prostate cancer, identifying genetic variants could allow treatment to be tailored based on a genetic profile in the early disease setting. Functional studies of identified variants are needed to fully understand underlying mechanisms of disease and identify novel targets for treatment. This review will outline the GWAS carried out in prostate cancer and the common variants identified so far, and how these may be utilized clinically in the screening for and management of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.